This article was corrected | View correction
In 1990, the International AIDS Conference was last held in the United States. The US Food and Drug Administration had approved only 1 antiretroviral drug to treat human immunodeficiency virus (HIV) infection (zidovudine, approved in 1987 [Figure]). Highly active antiretroviral therapy, which has made it possible to reduce the risk of HIV transmission and for infected individuals to live longer and healthier, was still 5 years in the future.1 The AIDS epidemic remained very much out of control in the United States and around the world. Each year brought many more infections and deaths, and the expanding pandemic threatened to overwhelm the capacity for an effective response.
Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more
Subscribe for full-text access to content from 1998 forward and a host of useful features
Activate your current subscription (AMA members and current subscribers)
Purchase Online Access to this article for 24 hours
AIDS surveillance case definition was expanded in 1993. FDA indicates US Food and Drug Administration; HIV, human immunodeficiency virus. Adapted from Centers for Disease Control and Prevention.1
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 2
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Users' Guides to the Medical Literature
For example, a trial of intravenous immunoglobulin in advanced human immunodeficiency infection...
The Rational Clinical Examination
Evidence Summary and Review 3
All results at
and access these and other features:
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.